Initiation, response assessment, and switch of antibody therapies in patients with severe asthma - A survey among German specialists.

"Declaration of competing interest HS reports fees for lectures or consultations from Astrazeneca, GSK, Novartis, Sanofi all outside the submitted work. DS reports fees for lectures or consultations from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Janssen, MSD, Sanofi, all outside the submitted work. KCB reports speaker fees from AstraZeneca, GSK, Novartis, Sanofi all outside the submitted work. CM no conflicts of interest. RB reports consulting fees or honoraria for lectures from ALK, AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, Cipla, GSK, Novartis, Roche, Sanofi, and TEVA, and grants to Mainz University Hospital for research or clinical trials, or both from Boehringer Ingelheim, GSK, Novartis, and Roche. RE no conflicts of interest. EH is funded by the German Ministry of Education and Research (BMBF) (CHAMP, Project Number: 01GL1742D) for characterisation of children and adolescents with severe asthma. He reports personal fees from ALK, Boehringer Ingelheim, GSK, Leti Pharma, Novartis, Nutricia, Sanofi, and Stallergenes all outside the submitted work. MI reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, Menarini, MSD, Novartis, Roche, Sanofi, all outside the submitted work. MJ no conflicts of interest. CS received personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Sanofi, all outside the submitted work. OS reports speaker fees from AstraZeneca, Novartis, Sanofi and Boehringer Ingelheim, all outside the submitted work. CT no conflicts of interest. KM reports speaker fees from AstraZeneca, GSK, Novartis, Sanofi, all outside the submitted work. SK reports speaker fees from AstraZeneca, GSK, Novartis, Sanofi, all outside the submitted work."

"Funding None."